Exchange: NASDAQ·Updated 07:47 PM EDT

GPCR News

News
all
press releases
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Zacks
More News
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
Zacks
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
Zacks
NVO Stock Logs Worst Week Since February As Novo Nordisk Rebrands To ‘Novo’ Amid Another Gloomy Year
NVO has fallen about 12% in 2026 after losing more than half its value in 2025, its worst year since 1984.
Stocktwits
Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data
Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.read more...
Benzinga
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Zacks
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.
Zacks
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
Zacks
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.
Zacks
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.
Zacks

Advertisement|Remove ads.